Different laboratories, studying different rodent models of diet-induced NASH, showed that pharmacological inhibition of Smo (vismodebig or LDE225) decreased activation of hedgehog pathway and consistently improved liver inflammation and fibrosis [61,69,71]. The gene discussed is SMO; the disease is metabolic dysfunction-associated steatohepatitis.